EAS Consensus Lowers Age and LDL-C Targets for Pediatric FH

This consensus statement recalibrates diagnostic thresholds, treatment initiation age, and LDL-C goals for children with familial hypercholesterolaemia, expanding the pharmacist's role in early lipid-lowering therapy.

familial hypercholesterolaemiaHeFHHoFHstatinsezetimibePCSK9 inhibitorsevinacumablomitapideinclisiranlipoprotein apheresispediatric dyslipidemiaLDL cholesterolcardiovascular preventionEAS consensusscreening Guideline: Dyslipidemia

Background Information

Early FH detection in children can extend life expectancy.

Early diagnosis and treatment of familial hypercholesterolaemia (FH) in children can significantly improve life expectancy and reduce the risk of premature cardiovascular disease. Revised diagnostic criteria and treatment goals for LDL cholesterol (LDL-C) in children with FH are presented, emphasizing early screening and initiation of lipid-lowering therapies (LLTs). The guideline highlights the need for pediatric FH screening programs and updated LDL-C treatment goals, which can enhance early intervention strategies. Implementing pediatric FH screening and early LLT can drastically improve long-term outcomes.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Wiegman A, Bourbon M, Freiberger T, Gidding SS, Greber-Platzer S, Groselj U, Holven KB, Hudgins LC, Humphries SE, Hutten BA, Ibarretxe D, Pederiva C, Peretti N, Raal FJ, Ramaswami U, Sanin V, Santos RD, Steinhagen-Thiessen E, Watts GF, Perkins R, Benn M, Binder CJ, Romeo S, Roeters van Lennep JE

Citation: Wiegman A, Bourbon M, Freiberger T, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. European heart journal. 2026;47(26):3324-3346. doi:10.1093/eurheartj/ehag382

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →